Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
612.77 K
Value Traded
10.50 M
Short % Float
4.46%
Days to Cover
3.3
+1.59%Week
-20.14%1 Month
+12.21%3 Month
-1.84%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.37 B
EPS (TTM)
-0.01
P/E Ratio
-
Ent. Value
1.37 B
Total Shares
107.45 M
Float Shares
76.17 M
Insiders
29.11%
Institutions
33.17%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
FRNM Catalyst Timeline
Dated clinical, regulatory and corporate events for Freenome, Inc. Common stock
Past FDA Catalysts and PDUFA Decisions
How FRNM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Freenome, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every FRNM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SimpleScreen CRC Breakthrough | colorectal cancer | 2026-10-11 | sensitivity crc: 80.4%; specificity: 90%; sensitivity apl: 18.2%; sensitivity apl hgd: 41.9%; previous sensitivity apl: 13.7%; previous sensitivity apl hgd: 30.5%Read More | Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FRNM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in FRNM for Q2 2026. | ||||
FRNM Institutional Ownership Trends
FRNM Short Interest
Shares sold short, counted twice a month.
4.46%
Short % of Float
of tradable shares sold short
3.4M
Shares Sold Short
+100.4% vs prior count
3.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.0M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FRNM ranks across every disease it competes in
Competitive Position is a premium feature
See how FRNM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFRNM News
-FRNM
Oct 20, 2026▲ +11.9%on this news
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
Freenome has launched SimpleScreen Lung, a blood test for lung cancer detection, which can be combined with its FDA-approved SimpleScreen CRC test for colorectal cancer. This dual testing approach aims to improve screening participation among eligible patients. The SimpleScreen Lung test demonstrated 85% sensitivity and a 99.8% negative predictive value in clinical validation, targeting adults aged 50 to 80 with a significant smoking history.
Read more →-FRNM
Oct 15, 2026Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
Freenome, Inc. plans to announce its financial results for Q3 2026 on November 10, 2026. The announcement will be followed by a conference call at 1:30 PM PT. The company focuses on developing blood-based tests for early cancer detection, utilizing a proprietary multiomics platform.
Read more →-FRNM
Oct 11, 2026▼ -16.2%on this newsshared move
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
Freenome, Inc. will present new validation data for its updated SimpleScreen CRC blood test at the ACG 2026 Annual Meeting. The test shows significant improvements in sensitivity for detecting advanced precancerous lesions, achieving 80.4% sensitivity for colorectal cancer detection. The updated version demonstrates enhanced performance compared to the original, indicating potential for better cancer prevention.
Read more →-FRNM
Aug 12, 2026FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
Freenome, Inc. announced that the FDA has granted Breakthrough Device Designation to its SimpleScreen Lung cancer screening test. This designation is aimed at adults aged 50 to 80 with a significant smoking history who are not currently screened for lung cancer. The test, which analyzes blood samples, seeks to improve early detection and accessibility of lung cancer screening.
Read more →-FRNM
Jul 27, 2026FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Freenome's SimpleScreen CRC, a blood-based colorectal cancer screening test, has received FDA approval, allowing Abbott to exclusively commercialize it in the U.S. The test targets adults aged 45 and older at average risk, aiming to improve screening rates among the 60 million Americans overdue for screening. With high sensitivity and specificity, it represents a significant advancement in early cancer detection.
Read more →-FRNM
Jul 20, 2026Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection
Freenome Holdings debuted on Nasdaq under ticker FRNM on July 21, 2026, after combining with Perceptive Capital Solutions Corp. The transaction generated over $300 million in gross proceeds. These funds support the company's AI-enabled multiomics platform and cancer screening portfolio. CEO Aaron Elliott stated the capital enables scaling personalized detection tests for unscreened Americans.
Read more →-FRNM
Jul 9, 2026Freenome Reports Top-Line Readout of Updated SimpleScreen™ CRC Colorectal Cancer Screening Blood Test Met All Primary and Secondary Endpoints
Freenome announced positive results from its updated SimpleScreen CRC test, achieving significant improvements in detecting advanced precancerous lesions and colorectal cancer. The study met all primary and secondary endpoints, showing high sensitivity rates. The updated test could lead to substantial reductions in colorectal cancer cases and deaths, enhancing screening accessibility.
Read more →-FRNM
May 27, 2026Freenome’s SimpleScreen™ CRC Blood-Based Test Included in Updated ACS Colorectal Cancer Screening Guideline
Freenome's SimpleScreen CRC blood test has been included in the updated ACS guidelines for colorectal cancer screening. This inclusion represents a shift towards non-invasive screening options, which may enhance patient participation. The test is currently under FDA review, with approval anticipated in mid 2026, and aims to improve access to screening.
Read more →-FRNM
Mar 18, 2026Freenome Reports Data for Multiomic Blood-Based Screening Test for Lung Cancer
Freenome announced promising data for its multiomic blood-based lung cancer screening test. The test achieved a sensitivity of 90.7% at 50% specificity, outperforming a methylation-only version. It detected lung cancer across all subtypes and stages. The data will be presented at the AACR Annual Meeting in April 2026.
Read more →-FRNM
Dec 8, 2025Freenome and Perceptive Capital Solutions Corp Announce Business Combination Agreement to Create a Publicly Listed Company Transforming Blood-Based Multi-Cancer Detection through an AI/ML-Enabled Multiomics Platform
Freenome Holdings, Inc. has entered a definitive agreement to merge with Perceptive Capital Solutions Corp, creating a publicly listed company focused on blood-based multi-cancer detection. The transaction, expected to close in the first half of 2026, includes a $240 million PIPE investment from leading healthcare investors. This merger aims to enhance Freenome's capabilities in early cancer detection through its AI/ML-enabled multiomics platform.
Read more →About Freenome, Inc. Common stock
Headquarters51 ASTOR PLACE, 10TH FLOOR, NEW YORK, NY, 10003
BIOPHARMAWATCH ELITE PLUS
Trade the next FRNM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime